ProfileGDS5678 / 1432185_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 24% 23% 23% 22% 22% 26% 22% 23% 22% 23% 23% 22% 43% 23% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.5848824
GSM967853U87-EV human glioblastoma xenograft - Control 22.5395123
GSM967854U87-EV human glioblastoma xenograft - Control 32.5436223
GSM967855U87-EV human glioblastoma xenograft - Control 42.4742122
GSM967856U87-EV human glioblastoma xenograft - Control 52.4791622
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.6667626
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.5605322
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.5172223
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.4978122
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.5258923
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.5248923
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.4930922
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.0157543
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.5325523